Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL therapy with pegylated interferon alfa and nivolumab in metastatic melanoma
NL-OMON56101Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous tumor-infiltrating lymphocytes, nivolumab and pegylated interferon alpha in melanoma and cutaneous melanoma (CM) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety and toxicity of TIL plus nivolumab and Safety and toxicity of TIL plus peginterferon alfa plus nivolumab. Started Jul 2018; status: recruiting.
02
Drugs
03
Conditions
melanomacutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON56101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56101.